Key statistics
On Tuesday, InnoCare Pharma Ltd (9969:HKG) closed at 11.18, 62.26% above the 52 week low of 6.89 set on Apr 09, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 11.42 |
|---|---|
| High | 11.79 |
| Low | 11.04 |
| Bid | -- |
| Offer | -- |
| Previous close | 11.52 |
| Average volume | 3.88m |
|---|---|
| Shares outstanding | 1.76bn |
| Free float | 1.20bn |
| P/E (TTM) | -- |
| Market cap | 25.21bn HKD |
| EPS (TTM) | -0.1411 HKD |
Data delayed at least 15 minutes, as of Mar 03 2026 08:08 GMT.
More ▼
- InnoCare’s next-generation TRKi Zurletrectinib Receives Priority Review for the Treatment of Pediatric Patients with Solid Tumors in China
- InnoCare Announces Key Developments of Critical Clinical Studies
- InnoCare Announces First Patient Dosed in the Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China
- InnoCare Announces IND Approval to Initiate Clinical Trial of VAV1 Degrader ICP-538 in China
- Study Results of Novel TYK2 Inhibitor Soficitinib in Patients with AD Published by JAMA Dermatology
- InnoCare Announces NMPA Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Cutaneous Lupus Erythematosus
- InnoCare Announces Approval of Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China
- InnoCare Announces Achievement of Primary Endpoint in Phase IIb Study of Orelabrutinib for SLE and Approval of Phase III Clinical Trial
- InnoCare Announces Approval of the Next-Generation TRK Inhibitor Zurletrectinib in China
- Over 20 Studies of InnoCare’s Orelabrutinib Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)
More ▼
